Small molecule inhibitors of KRAS g12d mutant
Small molecule inhibitors targeting the KRAS (G12D) protein address the inadequacies of current cancer treatments by modulating its activity, providing therapeutic benefits for cancers with high KRAS mutation frequencies.
WO2026136671A1PCT designated stage Publication Date: 2026-06-25MERCK SHARP & DOHME LLC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- MERCK SHARP & DOHME LLC
- Filing Date
- 2025-12-18
- Publication Date
- 2026-06-25
Smart Images
Figure IMGF000002_0001 
Figure IMGF000003_0001 
Figure IMGF000003_0002
Abstract
Compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Need to check novelty before this filing date? Find Prior Art